Does the media favor IONS or ABSI?

In the previous week, Absci had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 9 mentions for Absci and 6 mentions for Ionis Pharmaceuticals. Absci's average media sentiment score of 0.47 beat Ionis Pharmaceuticals' score of 0.25 indicating that Absci is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Absci 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ALKS or ABSI?

Alkermes has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 4.44 $241.66M $0.38 102.84 Absci $2.80M 535.67 -$115.18M -$0.80 N/A

Is ALKS or ABSI more profitable?

Alkermes has a net margin of 3.96% compared to Absci's net margin of -7,756.38%. Alkermes' return on equity of 4.15% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Absci -7,756.38% -61.71% -54.52%

Does the media refer more to ALKS or ABSI?

In the previous week, Absci had 5 more articles in the media than Alkermes. MarketBeat recorded 9 mentions for Absci and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.48 beat Absci's score of 0.47 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Absci 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ABSI or IMVT?

Absci has higher revenue and earnings than Immunovant. Absci is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Absci $2.80M 535.67 -$115.18M -$0.80 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is ABSI or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% Immunovant N/A -69.59% -62.49%

Does the media prefer ABSI or IMVT?

In the previous week, Immunovant had 5 more articles in the media than Absci. MarketBeat recorded 14 mentions for Immunovant and 9 mentions for Absci. Absci's average media sentiment score of 0.47 beat Immunovant's score of 0.27 indicating that Absci is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor IOVA or ABSI?

In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Absci. MarketBeat recorded 10 mentions for Iovance Biotherapeutics and 9 mentions for Absci. Iovance Biotherapeutics' average media sentiment score of 0.64 beat Absci's score of 0.47 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ABSI or GRAL?

Absci has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Absci $2.80M 535.67 -$115.18M -$0.80 N/A GRAIL $147.17M 42.40 -$408.35M -$9.75 N/A

Is ABSI or GRAL more profitable?

GRAIL has a net margin of -236.95% compared to Absci's net margin of -7,756.38%. GRAIL's return on equity of -15.88% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% GRAIL -236.95% -15.88% -14.02%

Does the media prefer ABSI or GRAL?

In the previous week, GRAIL had 4 more articles in the media than Absci. MarketBeat recorded 13 mentions for GRAIL and 9 mentions for Absci. Absci's average media sentiment score of 0.47 beat GRAIL's score of 0.47 indicating that Absci is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Absci (ABSI) Competitors

$8.74 -0.36 (-3.96%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$8.58 -0.16 (-1.88%)

As of 09:04 AM Eastern

Compare

ABSI vs. IONS, ALKS, IMVT, IOVA, and GRAL

Should you buy Absci stock or one of its competitors? Absci's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Immunovant (IMVT), Iovance Biotherapeutics (IOVA), and GRAIL (GRAL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Absci compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Absci had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 9 mentions for Absci and 6 mentions for Ionis Pharmaceuticals. Absci's average media sentiment score of 0.47 beat Ionis Pharmaceuticals' score of 0.25 indicating that Absci is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Absci	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Absci has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Ionis Pharmaceuticals currently has a consensus target price of $89.14, suggesting a potential upside of 108.77%. Absci has a consensus target price of $13.88, suggesting a potential upside of 58.75%. Given Ionis Pharmaceuticals' higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.74
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ionis Pharmaceuticals has a net margin of -64.76% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Absci	-7,756.38%	-61.71%	-54.52%

Absci has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	7.52	-$381.39M	-$3.46	N/A
Absci	$2.80M	535.67	-$115.18M	-$0.80	N/A

Summary

Absci beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Absci compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Absci had 5 more articles in the media than Alkermes. MarketBeat recorded 9 mentions for Absci and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.48 beat Absci's score of 0.47 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Absci	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes currently has a consensus price target of $54.47, suggesting a potential upside of 39.38%. Absci has a consensus price target of $13.88, suggesting a potential upside of 58.75%. Given Absci's stronger consensus rating and higher probable upside, analysts clearly believe Absci is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

95.2% of Alkermes shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 4.6% of Alkermes shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alkermes has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.44	$241.66M	$0.38	102.84
Absci	$2.80M	535.67	-$115.18M	-$0.80	N/A

Alkermes has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Absci has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market.

Alkermes has a net margin of 3.96% compared to Absci's net margin of -7,756.38%. Alkermes' return on equity of 4.15% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Absci	-7,756.38%	-61.71%	-54.52%

Summary

Alkermes beats Absci on 11 of the 17 factors compared between the two stocks.

How does Absci compare to Immunovant?

Absci (NASDAQ:ABSI) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Immunovant had 5 more articles in the media than Absci. MarketBeat recorded 14 mentions for Immunovant and 9 mentions for Absci. Absci's average media sentiment score of 0.47 beat Immunovant's score of 0.27 indicating that Absci is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Absci has higher revenue and earnings than Immunovant. Absci is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	535.67	-$115.18M	-$0.80	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Absci has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Absci currently has a consensus target price of $13.88, indicating a potential upside of 58.75%. Immunovant has a consensus target price of $44.00, indicating a potential upside of 57.71%. Given Absci's stronger consensus rating and higher possible upside, research analysts clearly believe Absci is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Immunovant has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Immunovant	N/A	-69.59%	-62.49%

52.1% of Absci shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Absci beats Immunovant on 12 of the 14 factors compared between the two stocks.

How does Absci compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Absci has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$324.97M	19.81	-$390.98M	-$0.73	N/A
Absci	$2.80M	535.67	-$115.18M	-$0.80	N/A

Iovance Biotherapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Absci has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market.

Iovance Biotherapeutics has a net margin of -89.11% compared to Absci's net margin of -7,756.38%. Iovance Biotherapeutics' return on equity of -40.51% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Absci	-7,756.38%	-61.71%	-54.52%

Iovance Biotherapeutics currently has a consensus price target of $13.20, indicating a potential downside of 7.11%. Absci has a consensus price target of $13.88, indicating a potential upside of 58.75%. Given Absci's stronger consensus rating and higher probable upside, analysts plainly believe Absci is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Absci. MarketBeat recorded 10 mentions for Iovance Biotherapeutics and 9 mentions for Absci. Iovance Biotherapeutics' average media sentiment score of 0.64 beat Absci's score of 0.47 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Iovance Biotherapeutics beats Absci on 8 of the 15 factors compared between the two stocks.

How does Absci compare to GRAIL?

Absci (NASDAQ:ABSI) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

GRAIL has a net margin of -236.95% compared to Absci's net margin of -7,756.38%. GRAIL's return on equity of -15.88% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
GRAIL	-236.95%	-15.88%	-14.02%

Absci currently has a consensus target price of $13.88, suggesting a potential upside of 58.75%. GRAIL has a consensus target price of $119.80, suggesting a potential downside of 14.24%. Given Absci's stronger consensus rating and higher possible upside, analysts clearly believe Absci is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

52.1% of Absci shares are held by institutional investors. 10.5% of Absci shares are held by company insiders. Comparatively, 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, GRAIL had 4 more articles in the media than Absci. MarketBeat recorded 13 mentions for GRAIL and 9 mentions for Absci. Absci's average media sentiment score of 0.47 beat GRAIL's score of 0.47 indicating that Absci is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Absci has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	535.67	-$115.18M	-$0.80	N/A
GRAIL	$147.17M	42.40	-$408.35M	-$9.75	N/A

Absci has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market. Comparatively, GRAIL has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market.

Summary

Absci beats GRAIL on 9 of the 15 factors compared between the two stocks.

Get Absci News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABSI vs. The Competition

Export

Metric	Absci	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.56B	$3.85B	$7.20B	$13.15B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-10.93	11.96	228.02	21.63
Price / Sales	535.67	1,130.24	556.21	70.18
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	6.94	16.05	10.33	5.92
Net Income	-$115.18M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-2.24%	-5.85%	-3.52%	-3.90%
1 Month Performance	10.08%	-12.90%	-7.78%	-6.42%
1 Year Performance	74.80%	2.97%	0.79%	-6.02%

Absci Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABSI Absci	2.8246 of 5 stars	$8.74 -4.0%	$13.88 +58.8%	+124.1%	$1.56B	$2.80M	N/A	140	Analyst Forecast Gap Up
IONS Ionis Pharmaceuticals	3.1795 of 5 stars	$43.50 -0.1%	$89.20 +105.1%	-40.2%	$7.24B	$944M	N/A	1,402	Analyst Upgrade
ALKS Alkermes	3.1757 of 5 stars	$42.76 +2.4%	$54.47 +27.4%	+22.4%	$7.00B	$1.48B	112.53	2,050
IMVT Immunovant	2.3932 of 5 stars	$33.25 -1.1%	$44.00 +32.3%	+59.5%	$6.94B	N/A	N/A	315
IOVA Iovance Biotherapeutics	2.0808 of 5 stars	$14.15 -0.5%	$12.40 -12.4%	+570.3%	$6.44B	$324.97M	N/A	975	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABSI) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Absci (ABSI) Competitors

ABSI vs. IONS, ALKS, IMVT, IOVA, and GRAL

How does Absci compare to Ionis Pharmaceuticals?

Summary

How does Absci compare to Alkermes?

Summary

How does Absci compare to Immunovant?

Summary

How does Absci compare to Iovance Biotherapeutics?

Summary

How does Absci compare to GRAIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Absci (ABSI) Competitors

ABSI vs. IONS, ALKS, IMVT, IOVA, and GRAL

How does Absci compare to Ionis Pharmaceuticals?

Do institutionals & insiders hold more shares of IONS or ABSI?

Does the media favor IONS or ABSI?

Which has more risk & volatility, IONS or ABSI?

Do analysts recommend IONS or ABSI?

Is IONS or ABSI more profitable?

Which has higher valuation and earnings, IONS or ABSI?

Summary

How does Absci compare to Alkermes?

Does the media refer more to ALKS or ABSI?

Do analysts rate ALKS or ABSI?

Do insiders & institutionals believe in ALKS or ABSI?

Which has stronger earnings and valuation, ALKS or ABSI?

Which has more volatility and risk, ALKS or ABSI?

Is ALKS or ABSI more profitable?

Summary

How does Absci compare to Immunovant?

Does the media prefer ABSI or IMVT?

Which has preferable earnings & valuation, ABSI or IMVT?

Which has more risk & volatility, ABSI or IMVT?

Do analysts rate ABSI or IMVT?

Is ABSI or IMVT more profitable?

Do insiders and institutionals believe in ABSI or IMVT?

Summary

How does Absci compare to Iovance Biotherapeutics?

Do institutionals & insiders have more ownership in IOVA or ABSI?

Which has better valuation and earnings, IOVA or ABSI?

Which has more risk & volatility, IOVA or ABSI?

Is IOVA or ABSI more profitable?

Do analysts prefer IOVA or ABSI?

Does the media favor IOVA or ABSI?

Summary

How does Absci compare to GRAIL?

Is ABSI or GRAL more profitable?

Do analysts prefer ABSI or GRAL?

Do insiders & institutionals hold more shares of ABSI or GRAL?

Does the media prefer ABSI or GRAL?

Which has stronger valuation & earnings, ABSI or GRAL?

Which has more volatility & risk, ABSI or GRAL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools